Objective: Coxsackievirus B3 (CVB3) is a dominant causative agent for viral myocarditis. So far, effective therapies for the treatment of the disease are not available. 20(S)-Protopanaxtriol is a major component of Panax pseudoginseng and has been clinically used for the treatment of heart diseases. However, it is not known whether 20(S)-protopanaxtriol exerts any anti-viral effects. Thus, the aim of this study was to investigate the therapeutic effects of 20(S)-protopanaxtriol against CVB3 in vivo and in vitro. Methods: The antiviral effects of 20(S)-protopanaxtriol in vitro were evaluated in HeLa cells infected by CVB3. Then, we examined the protective effects of 20(S)-protopanaxtriol on CVB3-induced myocarditis in BALB/c mice. These mice were treated with 20(S)-protopanaxtriol at doses of 100-400 mg.kg(-1).day(-1) for 7 days and compared with the controls. Results: We found that 20(S)-protopanaxtriol possessed potent antiviral effects on CVB3 in vitro. Compared with control mice, virus titers and pathological changes in the hearts were significantly decreased in the 20(S)-protopanaxtriol-treated group. Furthermore, biochemical markers of myocardial injury such as plasma lactate dehydrogenase and creatine kinase were decreased to normal levels. Conclusions: These data provide the possibility that 20(S)-protopanaxtriol can be used as a potential therapeutic means for treatment of viral myocarditis. Copyright (c) 2012 S. Karger AG, Basel
1.Jinan Univ, Natl Engn Res Ctr Genet Med, Guangzhou 510630, Guangdong, Peoples R China 2.Henan Inst Med Sci, Zhengzhou, Peoples R China 3.Chinese Acad Sci, Kunming Inst Bot, Kunming, Peoples R China 4.Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Mol Pathol, Tamaho, Yamanashi, Japan
Wang, Xiaoyan,Wang, Yafeng,Ren, Zhe,et al. Protective Effects of 20(S)-Protopanaxtriol on Viral Myocarditis Infected by Coxsackievirus B3[J]. PATHOBIOLOGY,2012,79(6):285-289.